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Abstract
Acute respiratory distress syndrome, also known as diffuse alveolar damage, is an acute injury to the lungs.
Patients experience severe shortness of breath and require mechanical ventilation. It is not a specific disease, but
an acute lung dysfunction associated with a variety of disorders: pneumonia, shock, sepsis, and trauma. A similar
lesion occurs in newborn infants, called hyaline disease of the newborn. It occurs in premature babies and has the
same pathophysiological mechanism as acute respiratory distress syndrome. Hyaline membranes are a pathologic
feature of acute respiratory distress syndrome, consisting of basophilic structures that coat alveolar surfaces. They
prevent oxygen exchange and are the basis of the lethality of this disorder. The syndrome is associated with very
high levels of hyaluronan in broncho-alveolar lavage specimens. We postulate that the hyaline membranes of acute
respiratory distress syndrome are hyaluronan-rich structures associated with serum hyaluronan-binding proteins such
as fibrinogen and fibrin. Potent infectious influenza viruses are recurrent pandemics and potential terrorist threats.
Lethality of influenza infection correlates with the presence of hyaline membranes. Installation of hyaluronidase as an
aerosol would provide a new treatment for acute respiratory respiratory distress syndrome, for which there has been no
new treatment in 45 years. The pig is the only species other than humans that develop hyaline membranes. Employing
this treatment in the porcine model would provide a direct test of the hypothesis.
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Introduction
Acute respiratory distress syndrome (ARDS) is a clinical
phenomenon [1] first described in 1967 [2]. A set of recalcitrant
respiratory disorders had been observed in a variety of patients that did
not respond to conventional therapies. ARDS is often a lethal disease.
No new treatment modality has been devised, even though this is a
wide spread problem and despite many efforts. A therapy for ARDS
is proposed here based on an aerosol of a recombinant enzyme. The
logistics behind such an approach is presented.

ARDS and hyaline membranes
ARDS is not considered a specific disease, but a disorder in
which there is acute lung dysfunction. It is associated with a variety
of disorders including pneumonia, shock, sepsis, chemical injury, and
trauma. It is one of the most severe forms of acute lung injury. Current
figures estimate that 200,000 cases occur per year in the US, with a
mortality rate of approximately 40% [3].
Since it is not a single disorder, a task force of pulmonary experts
in 2011 developed the “Berlin Definition” [4]. They proposed three
categories of ARDS based on degree of hypoxemia: mild, moderate
and severe. These were associated with increasing mortality, and thus,
will provide better informed clinical care and a more empirical patient
evaluation.
One of the characteristic features of ARDS in the human is the
development of hyaline membranes. This is a histologic feature of
pulmonary tissue from ARDS patients. Using haematoxylin and eosin
(H&E) staining, it is an amorphous pink acellular ribbon-like material
that binds to the walls of alveoli. These structures are thought to prevent
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air exchange between alveoli and capillaries imbedded in alveolar walls.
The clinical and pathological features closely resemble those observed
in premature infants, referred to as neonatal respiratory distress
syndrome (NRDS). Similar structures occur in the lungs of preterm
NRDS infants.

Neonatal respiratory distress syndrome
NRDS, formerly known as hyaline membrane disease of the newborn, is a serious respiratory disorder in the preterm infant [5]. The
syndrome is attributed to a deficiency in surfactant production and
structural immaturity of the lungs. It is the most common cause of
death in these preterm infants. An animal model has been obtained in
premature monkeys [6,7] that closely resembles the human disorder. It
is assumed that a similar pathophysiological mechanism is involved.

Influenza, past influenza epidemics and pandemics
Influenza is a negative stranded RNA virus. There have been many
virulent pandemics of influenza in the past. The most notorious is the
Spanish flu of 1918-1919. More people died of Spanish influenza in a
single year than in four-years of WWI, with a mortality rate of about
40%. Approximately 3% of the world’s population died, making it one
of the deadliest natural disasters in human history, with more deaths
than in the Black Death-Bubonic Plague of 1347 to 1351. More recent
epidemics include severe acute respiratory syndrome (SARS) of 20022003, and H1N1, known as the Swine flu of 2009, with 18,000 deaths
worldwide.
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Terrorist threats and anti-terrorist measures

Hyaluronan in ARDS

Genetically engineered influenza viruses have the potential of
becoming a basis of biological warfare and a major terrorist threat.
Preparation of such viruses for use in biological warfare is relatively
straight-forward. A high school biology class could accomplish this
bit of molecular genetics. Thus, it is absolutely necessary to become
prepared for such events, and to evolve protective strategies for such
contingencies. The present hypothesis provides precisely such a
measure. The hyaluronidase aerosol would be a universally effective
treatment modality, instantly available for all victims of such a potential
catastrophy.

There are major concentrations of HA that occur in ARDS [2].
Samples taken from broncho-alveolar lavage (BAL) specimens of ARDS
patients have markedly elevated HA levels. Less than 20 µg/ml of HA
occur in BAL samples from patients with normal lungs, while in two
studies, levels of 353 µg/ml and 515 µg/ml were observed, representing
20 to 25 times normal levels [18,19]. Increased HA deposition also occurs
in the premature monkey model of ARDS [7]. An excellent review of
the role of HA in acute lung injury is available [20]. Such data suggests
that hyaline membranes contain HA. There are copious levels of HA
in the inflamed lung, together with several HA-binding proteins. Such
proteins are present in plasma and in tissue exudates, which are filtrates
of plasma. Prominent among such HA-binding proteins are fibrinogen,
fibrin and its split products [21-23], and inter-alpha-inhibitor protein
family [24]. The latter not only stabilizes ECM structures such as
hyaline membranes, but is also hyaluronidase inhibitors [25]. All of
these features contribute to the argument that hyaline membranes are
stabilized HA-rich structures that are protected from the surrounding
catabolic activities that characterize inflammation.

Animal models for influenza infections and ARDS
A number of animal models are available for studying influenza
infections as well as for ARDS. The ferret reflects closely most features
of the human disease. They are exquisitely susceptible to infection with
human influenza viruses, express similar symptoms, and are the ideal small
animal model for research [8,9]. They also respond in a fashion similar to
humans the various immune responses including vaccination strategies.
Other animal models include rats, hamsters, and guinea pigs.
However none of these animals develop the hyaline membranes that
characterize ARDS in humans. The mortality of influenza infections
in humans correlates with hyaline membrane formation. Those that
succumb to infection have hyaline membranes, those that survive do
not on a nearly one to one basis (personal observations, RS). There is
only one experimental animal that does develop hyaline membranes,
and that is the pig [10]. No other influenza non-primate model does
so. Hyaline membranes in the pig have pathologic and histochemical
features identical to that in the human. There is one exception, and that
is the animal model for NRDS, the premature monkey [7].

The Mendelson syndrome for ARDS and hyaline
membrane formation
A major problem for the use of pigs in studying influenza-derived
ARDS and hyaline membranes is human infectivity. Pigs and humans
are susceptible to the same viruses. Influenza viruses exchange antigenic
epitopes easily and rapidly. Virulent infections may arise, even when
attenuated viruses are utilized initially. For this reason, a Biosafety
Laboratory-3 (BSL-3) facility is required. This is extremely expensive,
and very cumbersome for animal manipulation. Even small pig models
such as Yucatan pigs, micro-pigs, or young piglets present difficulties.
For this reason, a non-infective ARDS model is preferable.

Suppression of HA synthesis ameliorates acute lung
injuries
Further evidence for the role of HA in acute lung injury comes
from inhibitor studies. The drug 4-methylumbelliferone (4-MB) is a
potent inhibitor of hyaluronan synthesis [26]. Administered orally in
mice, it suppresses the intensity of the inflammatory response following
acute lung injury [27,28]. This provides additional evidence that HA
is associated with the inflammation in acute lung injury. The 4-MB is
available as a therapeutic in Europe, but not yet in the U.S.

Hyaline
The term “hyaline” used by Pathologists, has no biochemical
equivalent. It was described 150 years ago by German pathologists
before there was anything such thing as biochemistry. It was observed
by H&E staining, and various special stains, all fall-outs from the
aniline dye industry. A hyaline substance appears glassy and pink after
staining and is acellular. There have been no attempts to analyse hyaline
biochemically.

The Mendelson syndrome, the aspiration of gastric contents into
the lungs elicits hyaline membrane formation [11]. Inoculation of 0.1
M HCl into the pig through a bronchial tube reproduces the syndrome
rapidly and easily [10]. This provides a convenient non-infectious
alternative to influenza infection for studying hyaline membranes.

Hyaline therefore is an ambiguous term. We postulate that hyaline
staining may refer to HA-rich structures. This can be confirmed by
preincubation of tissue sections with a hyaluronidase. The proviso is
that most hyaluronidases are also chondroitinases that also degrade
chondroitin sulphate, albeit at a much slower rate. There is one
bacterial enzyme that is HA-specific, the one derived from Streptomyces
hyaluronlyticus. Many histochemical studies have failed to use
this enzyme. A step towards evaluating the HA content of hyaline
membranes in Pathology specimens would be to demonstrate loss of
staining of tissue sections following S. hyaluronlyticus incubation.

Hyaluronan

Hyaluronidases

Hyaluronan (HA, hyaluronic acid) is a straight chain
glycosaminoglycan (GAG) of the extracellular matrix (ECM) [12-14].
It is the major component of the ECM, particularly prominent during
development, regeneration and repair, and whenever there is rapid
tissue turnover. HA characterizes the stem cell niche [15]. HA is the
only GAG that that has no secondary modifications. It is not sulfated,
nor does it undergo epimerization reactions. HA also characterizes
tissues with infections and other inflammatory responses [16,17].
Evidence suggests that hyaline membranes are HA-rich structures.

Hyaluronidases are the hydrolase enzymes that catabolize HA
throughout the body of vertebrate. They are hydrolases rather than
the eliminases that occur in prokaryotes. The intrinsic difficulty in
measuring such hydrolases was the reason these were long neglected
enzymes [29]. This is in marked contrast with the bacterial enzyme
activity that can easily be followed by spectrophotometry. There are six
hyaluronidase-like sequences in the human genome, tightly clustered,
three each on chromosomes 3p and 7q [30,31]. Of these, two are
acid-active and are prominent in HA degradation in somatic tissues,
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HYAL1 and HYAL2. Both of these are present in the 3p cluster. The
third hyaluronidase-like sequence in this cluster is not associated with
a detectable enzyme activity. In the 7q gene cluster, one is a pseudogene,
transcribed but not translated. Another is a chondroitinase [32,33].
pH-20 appears to be the only hyaluronidase enzyme active at neutral
pH. It is associated with sperm and is involved in fertilization. The
latter enzyme has been commercialized in a recombinant form, and is
available as Hylenex® [34,35], a product of Halozyme Therapeutics, San
Diego, CA. A polyethylene-glycol cross-linked (PEGylated) form of the
enzyme is also being produced. The latter formulation has considerably
greater half-life following its administration.

Aerosols as drug treatment modalities
Hyaluronidase as a therapeutic agent administered as a nasal
spray for pulmonary delivery has not been attempted previously. The
pulmonary administration of medications through nasal aerosols has
been in use for decades. Corticosteroid inhalants are employed to
alleviate asthma and for patients with chronic obstructive pulmonary
disease [36]. There are many other successful examples of such uses.
Nano particles have been used for pulmonary drug delivery [37,38],
as well as spray-dried particles [39]. Enzymes have been utilized
previously as aerosol treatments. One of these is Pulmozyme®, a cocktail
of human recombinant deoxyribonuclease (DNAases or rhDNase) in
the management of cystic fibrosis. A precedent exists therefore for the
use of a hyaluronidase such as Hylenex® as a mode of treatment. This has
the potential of becoming a new and effective treatment for ARDS.

Serious provisos and potential drawbacks
The lung is an HA-rich structure, and even more so when there
is inflammation [40,16]. A serious drawback to our hypothesis, that
hyaluronidase can be a therapeutic measure for the treatment of
ARDS, is that it may make the condition even worse. Administered
enzyme could fragment existing HA-rich structures of the lung,
and thus intensify disease. Endogenous HA and its HA fragment
degradation products would flood the lung. Small HA polymers are
highly angiogenic, inflammatory, and immune-stimulatory [41,42].
HA fragments are themselves not only intrinsically inflammatory,
but also induce inflammatory cytokine expression [43,44]. It is
conceivable that the hyaluronidase enzyme treatment may intensify
rather than abate the inflammatory reaction. Thus there may be
serious consequences of hyaluronidase administration. This is a
situation that would be readily apparent in the porcine model using
the Mendelson syndrome. Titration of the volume of the HCl solution
administered in the pig model may be able to reproduce the three
levels of severity of ARDS: mild, moderate and severe. The levels
of hyaluronidase aerosol provided could perhaps be modulated
to maximize clinical response and also to avoid potential adverse
reactions.

Conclusion
It is postulated that the hyaline membranes in patients with ARDS
are HA-rich structures. This is an insoluble complex of HA together
with plasma HA-binding proteins that adhere to inflamed alveoli
preventing oxygen exchange. A recombinant form of the human
hyaluronidase enzyme PH20 can be administered as an aerosol to
ARDS patients. This will degrade hyaline membranes in these damaged
lungs and increase survival of such patients. It may become the first
effective treatment modality in several decades for ARDS in adults and
may also be effective for NRDS in premature infants. A porcine model
for ARDS, employing bronchial delivery of 0.1 M HCl to the lungs,
makes it possible to test this hypothesis.
J Pulm Respir Med, an open access journal
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